-
Tytuł:
-
Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae associated with invasive pneumococcal disease among adults in Japan.
-
Autorzy:
-
Yanagihara K; Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
Kosai K; Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
Mikamo H; Aichi Medical University Graduate School of Medicine, 1-1 Yazakokarimata, Aichi 480-1195, Japan.
Mukae H; Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
Takesue Y; Hyogo College of Medicine, 1-1 Mukogawacho, Nishinomiya, Hyogo 663-8501, Japan.
Abe M; MSD K.K., 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo 102-8667, Japan. Electronic address: .
Taniguchi K; MSD K.K., 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo 102-8667, Japan.
Petigara T; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, N.J. 07033, USA.
Kaku M; Tohoku Medical and Pharmaceutical University, 4-4-1 Komatsushima, Aobaku, Sendai, Miyagi 981-8558, Japan.
-
Źródło:
-
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2021 Jan; Vol. 102, pp. 260-268. Date of Electronic Publication: 2020 Oct 13.
-
Typ publikacji:
-
Journal Article; Observational Study
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Hamilton, ON : Elsevier
Original Publication: Hamilton, ON : Decker, c1996-
-
MeSH Terms:
-
Anti-Bacterial Agents/*pharmacology
Pneumococcal Infections/*microbiology
Streptococcus pneumoniae/*drug effects
Streptococcus pneumoniae/*isolation & purification
Adult ; Aged ; Aged, 80 and over ; Bacteremia/microbiology ; Cost of Illness ; Female ; Humans ; Immunocompromised Host ; Japan ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Pneumococcal Infections/prevention & control ; Pneumococcal Vaccines/immunology ; Prospective Studies ; Serogroup ; Serotyping ; Streptococcus pneumoniae/classification ; Vaccines, Conjugate/immunology
-
Contributed Indexing:
-
Keywords: Antimicrobial susceptibility; Invasive pneumococcal disease; Japan; Pneumococcal vaccines; Serotyping; Streptococcus pneumonia
-
Substance Nomenclature:
-
0 (Anti-Bacterial Agents)
0 (Pneumococcal Vaccines)
0 (Vaccines, Conjugate)
-
Entry Date(s):
-
Date Created: 20201016 Date Completed: 20210304 Latest Revision: 20210304
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.ijid.2020.10.017
-
PMID:
-
33065297
-
Objectives: This study evaluated the serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates from adults (aged ≥20 years) with invasive pneumococcal disease (IPD) in Japan.
Methods: This prospective observational study was conducted in 49 participating Japanese hospitals. S. pneumoniae isolates were serotyped and tested for antimicrobial susceptibility at a central laboratory. Information regarding patient characteristics, underlying disease, IPD clinical syndromes, and treatment was collected through medical chart review.
Results: The final analysis included 177 patients enrolled from 45 hospitals between September 2016 and April 2018 (bacteraemic pneumonia, 110; bacteraemia without identified focus, 29; meningitis, 19). Most patients (70.1%) were aged ≥65 years and most had underlying disease (79.1%). The proportion of isolates from serotypes contained in the pneumococcal polysaccharide vaccine (PPV) 23 was 61.0%, while those in the pneumococcal conjugate vaccine (PCV) 7 and PCV13 were 2.8% and 28.2%, respectively. Non-vaccine serotypes accounted for 37.9% of all isolates and 50.8% of isolates from immunosuppressed patients. Serotype 12F was the most common vaccine serotype, followed by serotype 3.
Conclusions: The continued disease burden of IPD in adults in Japan warrants improved vaccination rates and development of next-generation vaccines that include serotypes not currently covered.
Clinical Trial Registration: Clinical trial summary registration number 160,822,918,146; JapicCTI-163352.
(Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
